| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
34,081 |
22,923 |
$813K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
2,908 |
2,193 |
$68K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
41,391 |
24,951 |
$65K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
6,068 |
2,208 |
$25K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
619 |
470 |
$12K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
494 |
365 |
$8K |
| 99072 |
|
5,307 |
4,165 |
$195.66 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
21 |
20 |
$163.00 |
| 0003A |
|
18 |
16 |
$160.00 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
18 |
12 |
$158.74 |
| 87807 |
|
36 |
34 |
$101.58 |
| 91307 |
|
14 |
14 |
$0.12 |
| 91300 |
|
17 |
12 |
$0.04 |
| 91301 |
|
14 |
12 |
$0.03 |